Hypodiploidy is a major prognostic factor in multiple myeloma

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Multiple myeloma is a hematologic malignancy characterized by the proliferation of plasma cells.
• Chromosomal abnormalities are common in multiple myeloma and are associated with prognosis.
• Conventional karyotyping is a standard diagnostic tool for identifying these abnormalities.

Purpose of the Study:

• To evaluate the prognostic significance of chromosomal number patterns in newly diagnosed multiple myeloma.
• To compare overall survival (OS) between patients with hyperdiploid and hypodiploid karyotypes.
• To identify independent prognostic factors for OS in multiple myeloma.

Main Methods:

• Retrospective review of conventional karyotypes from 208 newly diagnosed multiple myeloma patients.
• Classification of patients into hyperdiploid (n=75) and hypodiploid (n=63) groups based on chromosome number.
• Survival analysis using Kaplan-Meier curves and Cox proportional hazards models.

Main Results:

• Hypodiploid karyotype was associated with significantly shorter median OS (12.6 months) compared to hyperdiploid (33.8 months) (P <.001).
• The presence of chromosome 13q abnormalities impacted OS in the overall series but not in complex chromosomal abnormality (CCA) patients.
• Hypodiploidy emerged as the strongest independent prognostic factor for OS (P <.001) in multivariate analysis.

Conclusions:

• The chromosome number pattern, particularly hypodiploidy, is a powerful independent prognostic factor in multiple myeloma.
• Karyotype analysis, specifically identifying hypodiploidy, can aid in risk stratification and treatment planning.
• These findings underscore the clinical utility of cytogenetic analysis in managing multiple myeloma.